Jianren Mao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jianren Mao has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Shuxing Wang
MGH Center for Translational Pain Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
20 shared publicationsGrewo Lim
MGH Center for Translational Pain Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
19 shared publicationsBackil Sung
MGH Center for Translational Pain Research Department of Anesthesia Critical Care and Pain Medicine Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA
13 shared publications- Lucy Chen
Massachusetts General Hospital, Harvard Medical School
12 shared publications Liling Yang
MGH Center for Translational Pain Research Department of Anesthesia Critical Care and Pain Medicine Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA
7 shared publicationsYinghong Tian
MGH Center for Translational Pain Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
7 shared publications
Latest Publications
- 1 October 2016
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 60 (5) , 220
Effect of 1.5% Topical Diclofenac on Clinical Neuropathic Pain
- 1 October 2016
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 60 (5) , 220
Effect of 1.5% Topical Diclofenac on Clinical Neuropathic Pain
- 13 November 2014
- Published by Springer Nature
- p. 59-65
NMDA Receptor Antagonists in the Treatment of Pain
- 13 November 2014
- Published by Springer Nature
- p. 59-65
NMDA Receptor Antagonists in the Treatment of Pain
- 1 August 2014
- Published by Wolters Kluwer Health in Pain
- Vol. 155 (8) , 1504-1515
Persistent nociception induces anxiety-like behavior in rodents: Role of endogenous neuropeptide S
Anxiety disorder is a comorbid condition of chronic pain. Analgesics and anxiolytics, subject to addiction and abuse, are currently used to manage pain and anxiety symptoms. However, the cellular mechanism underlying chronic pain and anxiety interaction remains to be elucidated. We report that persistent nociception following peripheral nerve injury induced anxiety-like behavior in rodents. Brain expression and release of neuropeptide S (NPS), a proposed endogenous anxiolytic peptide, was diminished in rodents with coexisting nociceptive and anxiety-like behaviors. Intracerebroventricular administration of exogenous NPS concurrently improved both nociceptive and anxiety-like behaviors. At the cellular level, NPS enhanced intra-amygdaloidal inhibitory transmission by increasing presynaptic gamma-aminobutyric acid (GABA) release from interneurons. These findings indicate that the interaction between nociceptive and anxiety-like behaviors in rodents may be regulated by the altered NPS-mediated intra-amygdaloidal GABAergic inhibition. The data suggest that enhancing the brain NPS function may be a new strategy to manage comorbid pain and anxiety.
- 1 August 2014
- Published by Wolters Kluwer Health in Pain
- Vol. 155 (8) , 1504-1515
Persistent nociception induces anxiety-like behavior in rodents: Role of endogenous neuropeptide S
Anxiety disorder is a comorbid condition of chronic pain. Analgesics and anxiolytics, subject to addiction and abuse, are currently used to manage pain and anxiety symptoms. However, the cellular mechanism underlying chronic pain and anxiety interaction remains to be elucidated. We report that persistent nociception following peripheral nerve injury induced anxiety-like behavior in rodents. Brain expression and release of neuropeptide S (NPS), a proposed endogenous anxiolytic peptide, was diminished in rodents with coexisting nociceptive and anxiety-like behaviors. Intracerebroventricular administration of exogenous NPS concurrently improved both nociceptive and anxiety-like behaviors. At the cellular level, NPS enhanced intra-amygdaloidal inhibitory transmission by increasing presynaptic gamma-aminobutyric acid (GABA) release from interneurons. These findings indicate that the interaction between nociceptive and anxiety-like behaviors in rodents may be regulated by the altered NPS-mediated intra-amygdaloidal GABAergic inhibition. The data suggest that enhancing the brain NPS function may be a new strategy to manage comorbid pain and anxiety.
- Open Access
- 1 May 2014
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 120 (5) , 1262-1274
Buprenorphine–Naloxone Therapy in Pain Management
Buprenorphine–naloxone (bup/nal in 4:1 ratio; Suboxone®; Reckitt Benckiser Pharmaceuticals Incorporation, Richmond, VA) is approved by the Food and Drug Administration for outpatient office-based addiction treatment. In the past few years, bup/nal has been increasingly prescribed off-label for chronic pain management. The current data suggest that bup/nal may provide pain relief in patients with chronic pain with opioid dependence or addiction. However, the unique pharmacological profile of bup/nal confers it to be a weak analgesic that is unlikely to provide adequate pain relief for patients without opioid dependence or addiction. Possible mechanisms of pain relief by bup/nal therapy in opioid-dependent patients with chronic pain may include reversal of opioid-induced hyperalgesia and improvement in opioid tolerance and addiction. Additional studies are needed to assess the implication of bup/nal therapy in clinical anesthesia and perioperative pain management.
- 1 May 2014
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 120 (5) , 1262-1274
Open AccessBuprenorphine–Naloxone Therapy in Pain Management
Buprenorphine–naloxone (bup/nal in 4:1 ratio; Suboxone®; Reckitt Benckiser Pharmaceuticals Incorporation, Richmond, VA) is approved by the Food and Drug Administration for outpatient office-based addiction treatment. In the past few years, bup/nal has been increasingly prescribed off-label for chronic pain management. The current data suggest that bup/nal may provide pain relief in patients with chronic pain with opioid dependence or addiction. However, the unique pharmacological profile of bup/nal confers it to be a weak analgesic that is unlikely to provide adequate pain relief for patients without opioid dependence or addiction. Possible mechanisms of pain relief by bup/nal therapy in opioid-dependent patients with chronic pain may include reversal of opioid-induced hyperalgesia and improvement in opioid tolerance and addiction. Additional studies are needed to assess the implication of bup/nal therapy in clinical anesthesia and perioperative pain management.
- 1 May 2014
- Published by Elsevier in Brain Research
- Vol. 1564, 52-61
Midazolam exacerbates morphine tolerance and morphine-induced hyperactive behaviors in young rats with burn injury
- 1 May 2014
- Published by Elsevier in Brain Research
- Vol. 1564, 52-61
Midazolam exacerbates morphine tolerance and morphine-induced hyperactive behaviors in young rats with burn injury
- 1 October 2013
- Published by Elsevier in Brain Research
- Vol. 1535, 137-147
Spinal expression of Hippo signaling components YAP and TAZ following peripheral nerve injury in rats
- 1 October 2013
- Published by Elsevier in Brain Research
- Vol. 1535, 137-147
Spinal expression of Hippo signaling components YAP and TAZ following peripheral nerve injury in rats
- Open Access
- 11 September 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (9) , e74533
Disruption of Persistent Nociceptive Behavior in Rats with Learning Impairment
Despite the subjective nature of pain experience with cognitive and affective dimensions, preclinical pain research has largely focused on its sensory dimension. Here, we examined the relationship between learning/memory and nociceptive behavior in rats with combined learning impairment and persistent nociception. Learning impairment was induced by bilateral hippocampal injection of a mixed Aβ solution, whereas persistent nociception produced in these rats by complete Freund’s adjuvant-induced ankle inflammation. Those rats with learning impairment showed a diminished development of thermal hyperalgesia and mechanical allodynia and a shorter time course of nociceptive behavior without alteration of their baseline nociceptive threshold. In rats with pre-established hyperalgesia and allodynia due to ankle inflammation, bilateral intra-hippocampal injection of cycloheximide (a protein synthesis inhibitor) promoted the earlier recovery of nociceptive behavior. Moreover, expression of Aβ, NR1 subunit of the N-methyl-D-aspartate receptor, and protein kinase Cγ was upregulated, whereas the choline acetyl transferase expression was downregulated, in the hippocampus, thalamus, amygdala, and/or spinal cord of rats with combined learning impairment and persistent nociception. The data indicate that learning impairment could disrupt the response to a state of persistent nociception, suggesting an important role for cognitive maladaptation in the mechanisms of chronic pain. These results also suggest that a preclinical model of combined learning impairment and persistent nociception may be useful to explore the brain mechanisms underlying the transition from acute to chronic pain.
- 11 September 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (9) , e74533
Open AccessDisruption of Persistent Nociceptive Behavior in Rats with Learning Impairment
Despite the subjective nature of pain experience with cognitive and affective dimensions, preclinical pain research has largely focused on its sensory dimension. Here, we examined the relationship between learning/memory and nociceptive behavior in rats with combined learning impairment and persistent nociception. Learning impairment was induced by bilateral hippocampal injection of a mixed Aβ solution, whereas persistent nociception produced in these rats by complete Freund’s adjuvant-induced ankle inflammation. Those rats with learning impairment showed a diminished development of thermal hyperalgesia and mechanical allodynia and a shorter time course of nociceptive behavior without alteration of their baseline nociceptive threshold. In rats with pre-established hyperalgesia and allodynia due to ankle inflammation, bilateral intra-hippocampal injection of cycloheximide (a protein synthesis inhibitor) promoted the earlier recovery of nociceptive behavior. Moreover, expression of Aβ, NR1 subunit of the N-methyl-D-aspartate receptor, and protein kinase Cγ was upregulated, whereas the choline acetyl transferase expression was downregulated, in the hippocampus, thalamus, amygdala, and/or spinal cord of rats with combined learning impairment and persistent nociception. The data indicate that learning impairment could disrupt the response to a state of persistent nociception, suggesting an important role for cognitive maladaptation in the mechanisms of chronic pain. These results also suggest that a preclinical model of combined learning impairment and persistent nociception may be useful to explore the brain mechanisms underlying the transition from acute to chronic pain.
- 26 July 2013
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 17 (9) , 1-8
Update on Neuropathic Pain Treatment: Ion Channel Blockers and Gabapentinoids
Neuropathic pain is a debilitating chronic pain condition, which remains difficult to treat. The current mainstays of treatment include physical therapy, interventional procedures and medications. Among medications, ion channel blockers and gabapentinoids are the 2 classes of drugs commonly used to treat neuropathic pain. It has been suggested that these medications may be useful to treat a variety of neuropathic pain conditions. This article provides several updates on the utility of both ion channel blockers and gabapentinoids for the treatment of neuropathic pain.
- 26 July 2013
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 17 (9) , 1-8
Update on Neuropathic Pain Treatment: Ion Channel Blockers and Gabapentinoids
Neuropathic pain is a debilitating chronic pain condition, which remains difficult to treat. The current mainstays of treatment include physical therapy, interventional procedures and medications. Among medications, ion channel blockers and gabapentinoids are the 2 classes of drugs commonly used to treat neuropathic pain. It has been suggested that these medications may be useful to treat a variety of neuropathic pain conditions. This article provides several updates on the utility of both ion channel blockers and gabapentinoids for the treatment of neuropathic pain.
- 1 March 2013
- Published by Oxford University Press (OUP)
- p. 3-34
Opioids
- 1 January 2013
- Published by Springer Nature
- p. 1383-1387
Glutamate Homeostasis and Opioid Tolerance